Data on Acute Lymphoblastic Leukemia Reported by Sohita Dhillon and Colleagues (Inotuzumab Ozogamicin: First Pediatric Approval).
In: Pediatrics Week, 2024-06-07, S. 97-97
serialPeriodical
Zugriff:
A recent report discusses the development and approval of inotuzumab ozogamicin, a drug used to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients. Inotuzumab ozogamicin is a CD22-targeted monoclonal antibody drug conjugate that binds to CD22-expressing tumor cells, delivering a cytotoxic agent that induces cell cycle arrest and apoptotic cell death. The drug has received approval in the USA, Europe, and Japan for this indication. The report provides an overview of the milestones in the development of inotuzumab ozogamicin leading to its first pediatric approval. [Extracted from the article]
Copyright of Pediatrics Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Data on Acute Lymphoblastic Leukemia Reported by Sohita Dhillon and Colleagues (Inotuzumab Ozogamicin: First Pediatric Approval).
|
---|---|
Zeitschrift: | Pediatrics Week, 2024-06-07, S. 97-97 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1944-2637 (print) |
Schlagwort: |
|
Sonstiges: |
|